Clinical Trial Update: Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula [NA]

View source ↗

Summary

A completed clinical trial evaluating phosphodiesterase type 5 inhibition to improve endothelial function and vascular remodeling in chronic kidney disease and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Endothelial Dysfunction

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Improve Endothelial Function and Decrease Vascular Stenosis | NA | Status: COMPLETED | Results posted: 2018-08-21